RA (n=432) | axSpA (n=240) | Total (n=672) | |
Age (years) | n=368 58.3±13.1 | n=207 47.0±13.2 | n=575 54.2±14.2 |
Gender | n=373 | n=208 | n=581 |
Female | 276 (74.0%) | 94 (45.2%) | 370 (63.7%) |
Male | 97 (26.0%) | 114 (54.8%) | 211 (36.3%) |
Professional activity | n=424 | n=237 | n=661 |
In employment | 162 (38.2%) | 167 (70.5%) | 329 (49.8%) |
Student | 2 (0.5%) | 1 (0.4%) | 3 (0.5%) |
Unemployed | 8 (1.9%) | 19 (8.0%) | 27 (4.1%) |
Retired | 201 (47.4%) | 30 (12.7%) | 231 (34.9%) |
Other | 51 (12.0%) | 20 (8.4%) | 71 (10.7%) |
Education level | n=427 | n=238 | n=665 |
Primary | 77 (18.0%) | 11 (4.6%) | 88 (13.2%) |
Secondary | 219 (51.3%) | 134 (56.3%) | 353 (53.1%) |
Tertiary | 131 (30.7%) | 93 (39.1%) | 224 (33.7%) |
Disease duration (years) | n=358 | n=203 | n=561 |
13.1±11.4 | 13.8±10.6 | 13.4±11.1 | |
Disease activity | n=427 | n=236 | |
DAS28 | 2.6±1.2 | – | – |
BASDAI | – | 3.3±2.2 | – |
Physician global assessment of disease activity (NRS) | n=419 | n=232 | n=651 |
2.75±2.12 | 3.44±2.41 | 3.00±2.25 | |
Patient global assessment of disease activity (NRS) | n=382 | n=216 | n=598 |
3.03±2.45 | 4.27±2.61 | 3.48±2.58 | |
Treatments | n=326 | n=238 | n=564 |
None | 5 (1.5%) | 7 (2.9%) | 12 (2.1%) |
Corticosteroids alone | 6 (1.8%) | – | 6 (1.1%) |
NSAIDs alone | – | 36 (15.1%) | 36 (6.4%) |
Synthetic DMARDs ± corticosteroids | 61 (18.7%) | – | 61 (10.8%) |
Synthetic DMARDs ± NSAIDs | – | 15 (6.3%) | 15 (2.7%) |
Biological DMARDs (alone or in combination) | 252 (77.3%) | 173 (72.7%) | 425 (75.4%) |
Other | 2 (0.6%) | 7 (2.9%) | 9 (0.7%) |
Data are presented as mean values±SD for continuous variables, and as frequency counts (%) for categorical variables.
axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS28, 28-item Disease Activity Score; DMARD, disease-modifying antirheumatic drug; NRS, numerical rating scale; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis.